Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia

Condition(s) targeted: Schizophrenia

Intervention: Oxcarbazepine (Drug); Placebo (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: University of Cologne

Official(s) and/or principal investigator(s):
F. Markus Leweke, MD, Study Director, Affiliation: University of Cologne

Overall contact:
F. Markus Leweke, MD, Phone: +49 (221) 478 7250, Email: m.leweke@uni-koeln.de

Over recent years an approach with the adjunctive administration of various anticonvulsant drugs has been discussed and a limited number of open and controlled studies were performed for carbamazepine, valproic acid, and lamotrigine. While the latter shows promising effects in the long run it has some handling difficulties in the acute treatment of acute psychotic exacerbations. Valproic acid has shown inconsistent effects in schizophrenia with no significant effects in a recent controlled study. Although still controversially discussed, carbamazepine was found to offer beneficial effects in the treatment of schizophrenia. Nonetheless, data on these effects are limited by small sample sizes or poor design of most of the respective studies. Furthermore, the complex pharmaco-logical interactions of new atypical neuroleptics with carbamazepine underline the necessity of alternative strategies in adjuvant treatment of schizophrenia as well as in combined treatment of bipolar disorders with mood stabilizers and neuroleptics.

Oxcarbazepine (OXC) is a new anticonvulsant drug that acts as a pro-drug for the 10-monohydroxy metabo-lite (MHD), an active metabolite also of carbamazepine that is suggested to be responsible for most of its therapeutic actions. Therefore, the pharmacological action of OXC is very well comparable to carbamazepine whilst there are fewer unwanted side effects of OXC regarding eg. skinrush, and effects on blood compounds or cardiotropic effects.

The effects of OXC on cytochrome CYP3A4 and CYP3A5 are moderate and UDPGT is only slightly affected by OXC, which leads to less interaction with other compounds on a pharmacokinetical level.

In psychiatry, the few studies published until now report positive effects of OXC in bipolar disorders. With regards to our own clinical observations, OXC has shown potential beneficial effects as an adjunct in the treatment of schizophrenia as well that require further evaluation in a controlled study design.

Official title: Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Amount of Olanzapine Co-medication

Secondary outcome:

BPRS

Extrapyramidal symptoms

Weigth gain

Prolactin levels in plasma

ECG QT-C time elongation

Neurocognitive performance

Detailed description: This is an explorative controlled study with Oxcarbazepine (OXC) as an adjunct in the acute treatment of schizophrenia. The study will be performed in subjects between 18 and 50 years of age with an acute schizophrenic or schizophreniform disorder according to DSM-IV. The study will be performed according to Guidelines for Good Clinical Practice (GCP).

The primary hypothesis of this study is that adjunctive treatment with OXC yields at least comparable efficacy regarding antipsychotic actions with lower doses of neuroleptics and consequently substantially fewer adverse events.

A randomised controlled, double blind study is intended. During a 6 weeks treatment trial two groups of pa-tients will be basically treated with olanzapine (starting with 5 mg after one week with an optional, BPRS-controlled step by step increase of about 2,5 mg each following week). Patients will receive a placebo controlled adjunctive therapy with OXC (1800 mg/day). After the initial lead-in of OXC within 7 days (allowing lorazepam as comedication), treatment with olanzapine will be started. Based on biometric calculations, a drop out adjusted sample size of 222 inpatients will be necessary

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Clinical diagnosis of schizophrenia or schizophreniform psychosis according to DSM-IV

- BPRS score >36 and BPRS psychosis cluster > 12

- Ability to provide written informed consent

- Participants are required an adequate contraception

Exclusion Criteria:

- Any severe neurological or somatic disorder

- Other psychiatric disorders including addictive disorders

- Positive urine drug screening for any compound except benzodiazepines

- No pregnancy or breast feeding

F. Markus Leweke, MD, Phone: +49 (221) 478 7250, Email: m.leweke@uni-koeln.de

Isar-Amper-Klinikum gemeinnützige GmbH, Klinik Taufkirchen (Vils), Taufkirchen (Vils), Bayern 84416, Germany; Active, not recruiting

University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne, NRW 50924, Germany; Recruiting
F. Markus Leweke, MD, Phone: +49 (221) 478 7250, Email: m.leweke@uni-koeln.de
Dagmar Koethe, MD, Phone: +49 (221) 478 86231, Email: koethe@ecnp.net
Christoph W Gerth, MD, Sub-Investigator
F. Markus Leweke, MD, Principal Investigator
Dagmar Koethe, MD, Sub-Investigator
Brit M Nolden, MD, Sub-Investigator
Tobias Buzello, MD, Sub-Investigator

Starting date: July 2004
Ending date: July 2008
Last updated: March 10, 2008